Skip to main content

Table 5 Multivariate analysis

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

 

Relapse

NRM

Acute GVHD

Chronic GVHD

LFS

OS

 

p value

HR (95 % CI)

p value

HR (95 % CI)

p value

OR (95 % CI)

p value

HR (95 % CI)

p value

HR (95 % CI)

p value

HR (95 % CI)

HLA 10/10 (ref)

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

HLA 9/10 versus 10/10

0.038

1.18 (1.01–1.38)

0.001

1.34 (1.13–1.58)

0.0001

1.47 (1.21–1.79)

0.418

1.07 (0.91–1.26)

0.0001

1.25 (1.11–1.40)

0.0001

1.27 (1.13–1.44)

HLA 8/10 versus 9/10

0.064

0.67 (0.43–1.02)

0.398

1.17 (0.81–1.68)

0.952

1.01 (0.63–1.62)

0.145

1.31 (0.91–1.88)

0.432

0.90 (0.68–1.18)

0.557

0.92 (0.69–1.22)

Age at SCT (10 years)

0.701

1.02 (0.91–1.15)

<10−5

1.41 (1.24–1.59)

0.465

1.05 (0.91–1.22)

0.501

1.04 (0.93–1.17)

0.0001

1.18 (1.09–1.29)

<10−5

1.25 (1.14–1.37)

Interval diag. to SCTa

0.007

0.96 (0.93–0.99)

0.636

1.01 (0.98–1.03)

0.306

0.98 (0.95–1.02)

0.833

1.00 (0.97–1.02)

0.108

0.98 (0.96–1.00)

0.122

0.98 (0.96–1.00)

Disease status at SCT

            

CR1 (ref)

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

CR2 versus CR1

4.10−5

1.50 (1.24–1.82)

0.713

1.04 (0.85–1.28)

0.728

1.04 (0.82–1.32)

0.558

1.06 (0.88–1.28)

0.002

1.25 (1.09–1.44)

0.016

1.20 (1.03–1.39)

Act.dis. versus CR1

<10−5

2.06 (1.76–2.42)

0.001

1.35 (1.14–1.60)

0.004

1.34 (1.1–1.63)

0.019

1.22 (1.03–1.45)

<10−5

1.69 (1.51–1.90)

<10−5

1.63 (1.44–1.84)

Secondary AML

0.699

0.97 (0.83–1.13)

0.0004

1.32 (1.13–1.54)

0.418

1.08 (0.90–1.30)

0.196

1.11 (0.95–1.29)

0.029

1.13 (1.01–1.26)

0.021

1.14 (1.02–1.28)

Karnofsky ≥80 %

0.149

0.83 (0.64–1.07)

<10−5

0.55 (0.43–0.70)

0.838

0.97 (0.70–1.33)

0.318

0.86 (0.64–1.16)

10−5

0.68 (0.57–0.81)

<10−5

0.63 (0.58–0.76)

TBI

0.005

1.26 (1.07–1.48)

0.767

1.03 (0.85–1.24)

0.088

0.83 (0.67–1.03)

0.610

1.04 (0.88–1.24)

0.019

1.16 (1.02–1.30)

0.022

1.16 (1.02–1.32)

In vivo T cell depletion

0.483

1.07 (0.89–1.27)

0.253

0.90 (0.74–1.08)

<10−5

0.61 (0.49–0.75)

0.0001

0.72 (0.61–0.85)

0.790

0.98 (0.86–1.12)

0.72

0.98 (0.85–1.12)

Female D to male R

0.112

0.84 (0.68–1.04)

0.172

1.15 (0.94–1.42)

0.063

1.26 (0.99–1.61)

0.078

1.19 (0.98–1.45)

0.846

0.99 (0.85–1.14)

0.896

1.01 (0.87–1.18)

High CMV risk (R+/D−)

0.665

1.04 (0.87–1.24)

0.002

1.35 (1.11–1.65)

0.028

1.28 (1.03–1.60)

0.814

0.98 (0.82–1.17)

0.019

1.17 (1.03–1.33)

0.001

1.25 (1.09–1.43)

  1. Act.dis. active disease, CR complete remission, D donor, D− donor, CMV serology, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, PB Peripheral blood, Ref reference, R recipient, R+ positive recipient, CMV serology, SCT allogeneic stem cell transplantation, TBI total body irradiation
  2. aAnalyzed per 6-month interval
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us